Stock Events

Stock Events

Phio Pharmaceuticals 

$1.0300
56
-$0.05-4.63% Thursday 20:00

Statistics

Day High
1.1
Day Low
1.03
52W High
4.19
52W Low
0.813
Volume
476,166
Avg. Volume
-
Mkt Cap
11.09M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-4.59
-3.14
-1.69
-0.24
Expected EPS
-0.36
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-14.3MNet Income

Analyst Ratings

14.00Average Price Target
The highest estimate is 14.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PHIO. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap19.8B
Moderna is a leader in mRNA technology, competing in the broader field of genetic medicines, similar to Phio's RNAi therapeutics approach.
Alnylam Pharmaceuticals
ALNY
Mkt Cap37.76B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, directly competing with Phio's core technology and product pipeline.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap10.5B
Arrowhead Pharmaceuticals focuses on developing RNAi therapeutics for a variety of diseases, making it a direct competitor.
Ionis Pharmaceuticals
IONS
Mkt Cap12.11B
Ionis Pharmaceuticals is a leader in RNA-targeted drug discovery and development, competing in the same space as Phio.
Sarepta Therapeutics
SRPT
Mkt Cap1.62B
Sarepta Therapeutics focuses on RNA-based therapies, particularly for rare diseases, overlapping with Phio's therapeutic areas.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.81B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals, including RNA-based products, competing in the genetic disease market.
CRISPR Therapeutics
CRSP
Mkt Cap4.9B
CRISPR Therapeutics is focused on developing gene-based medicines, including CRISPR/Cas9 technology, which competes in the broader genetic medicine space.
Intellia Therapeutics
NTLA
Mkt Cap1.69B
Intellia Therapeutics is a leading developer of CRISPR gene editing, competing in the genetic medicine field alongside companies like Phio.

About

Phio Pharmaceuticals Corp. is a U.S.-based company dedicated to creating immune-system-focused cancer treatments. Their proprietary INTASYL therapeutic platform aims to influence both tumor and immune cells through the precise regulation of immune system genes. The company's pipeline includes several key candidates for adoptive cell transfer (ACT): PH-762 works by diminishing the expression of the PD-1 checkpoint protein, thereby empowering immune cells to identify and eliminate cancerous cells; PH-894, another candidate, silences BRD4, an epigenetic protein crucial for intracellular gene expression regulation; and PH-804 is designed to target TIGIT, a suppressive immune receptor and checkpoint protein found on T cells and natural killer cells. Furthermore, the company maintains a partnership with AgonOx Inc. to advance the clinical development of innovative T cell-based immunotherapies for cancer. Incorporated in 2011, Phio Pharmaceuticals Corp., headquartered in Marlborough, Massachusetts, adopted its current name in November 2018, having previously operated as RXi Pharmaceuticals Corporation.
Show more...
CEO
Mr. Robert J. Bitterman
Employees
5
Country
United States
ISIN
US71880W5013

Listings

MU
DE
44R0.MU
XNAS
US
PHIO
BOATS
BOATS
PHIO.BOATS

0 Comments

Share your thoughts

FAQ

What is Phio Pharmaceuticals stock price today?▼
The current price of PHIO is $1.03 USD — it has decreased by -4.63% in the past 24 hours. Watch Phio Pharmaceuticals stock price performance more closely on the chart.
What is Phio Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Phio Pharmaceuticals stocks are traded under the ticker PHIO.
Is Phio Pharmaceuticals stock price growing?▼
PHIO stock has fallen by -6.36% compared to the previous week, the month change is a -5.5% fall, over the last year Phio Pharmaceuticals has showed a -54.53% decrease.
What is Phio Pharmaceuticals market cap?▼
Today Phio Pharmaceuticals has the market capitalization of 11.09M
When is the next Phio Pharmaceuticals earnings date?▼
Phio Pharmaceuticals is going to release the next earnings report on August 06, 2026.
What were Phio Pharmaceuticals earnings last quarter?▼
PHIO earnings for the last quarter are -0.34 USD per share, whereas the estimation was -0.24 USD resulting in a -44.68% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Phio Pharmaceuticals revenue for the last year?▼
Phio Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Phio Pharmaceuticals net income for the last year?▼
PHIO net income for the last year is -14.3M USD.
How many employees does Phio Pharmaceuticals have?▼
As of June 22, 2026, the company has 5 employees.
In which sector is Phio Pharmaceuticals located?▼
Phio Pharmaceuticals operates in the Health & Wellness sector.
When did Phio Pharmaceuticals complete a stock split?▼
The last stock split for Phio Pharmaceuticals was on July 05, 2024 with a ratio of 1:9.
Where is Phio Pharmaceuticals headquartered?▼
Phio Pharmaceuticals is headquartered in King of Prussia, United States.